key: cord-0715449-ba8eo62q
authors: Carreno, J. M.; Raskin, A.; Singh, G.; Tcheou, J.; Kawabata, H.; Gleason, C.; Srivastava, K.; Vigdorovich, V.; Dambrauskas, N.; Gupta, S. L.; Gonzalez, I.; Martinez, J. L.; Slamanig, S.; Sather, D. N.; Raghunandan, R.; Wirachwong, P.; Muangnoicharoen, S.; Pitisuttithum, P.; Wrammert, J.; Suthar, M. S.; Sun, W.; Palese, P.; Garcia-Sastre, A.; Simon, V.; Krammer, F.
title: The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines
date: 2022-01-28
journal: nan
DOI: 10.1101/2022.01.25.22269808
sha: 3a3d7612b12d2c781d32476c267fb218b0e144f9
doc_id: 715449
cord_uid: ba8eo62q

NDV-HXP-S is a recombinant Newcastle disease virus based-vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be produced in embryonated chicken eggs using the same process as that employed for the production of influenza virus vaccines. Here we performed a secondary analysis of the antibody responses after vaccination with inactivated NDV-HXP-S in a Phase I clinical study in Thailand. The SARS-CoV-2 neutralizing and spike binding activity of NDV-HXP-S post-vaccination serum samples was compared to that of matched samples from mRNA BNT162b2 (Pfizer) vaccinees. Neutralizing activity of sera from NDV-HXP-S vaccinees was comparable to that of individuals vaccinated with BNT162b2. Interstingly, the spike binding activity of the NDV-HXP-S vaccinee samples was lower than that of sera obtained from individuals vaccinated with the mRNA vaccine. This let us to calculate ratios between binding and neutralizing antibody titers. Samples from NDV-HXP-S vaccinees had binding to neutralizing activity ratios similar to those of convalescent sera suggesting a very high proportion of neutralizing antibodies and low non-neutralizing antibody titers. Further analysis showed that, in contrast to mRNA vaccination, which induces strong antibody titers to the receptor binding domain (RBD), the N-terminal domain, and the S2 domain, NDV-HXP-S vaccination induces a very RBD focused response with little reactivity to S2. This explains the high proportion of neutralizing antibodies since most neutralizing epitopes are located in the RBD. In conclusion, vaccination with inactivated NDV-HXP-S induces a high proportion of neutralizing antibodies and absolute neutralizing antibody titers comparable to those after mRNA vaccination.

A large number of vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been 57 developed and licensed (1). Nevertheless, there is a need for SARS-CoV-2 vaccines that can be produced 58 at low cost locally in low-and middle-income countries (LMICs). The NDV-HXP-S vaccine (2) is based on a 59

Newcastle disease virus (NDV) vector which presents a stabilized HexaPro (3) version of the spike protein 60 on its surface. This vaccine can be manufactured like influenza virus vaccines at low cost in embryonated 61 chicken eggs in facilities located globally, including in LMICs (2, 4-6). NDV-HXP-S can be used as live vaccine 62

(2, 7, 8) or as an inactivated vaccine (2, 9) . Clinical trials with a live version are ongoing in Mexico 63 (NCT04871737) and the US (NCT05181709), while the inactivated vaccine is being tested in Vietnam 64 (NCT04830800), Thailand (NCT04764422,) and Brazil (NCT04993209). Results from the initial Phase I trials 65

are promising and Phase I data from Thailand with the inactivated vaccine have been reported (9). Phase 66 II trials with the inactivated vaccine have also been successfully conducted, while Phase III trials are 67 currently in the planning stage. 68

It has been shown that both natural infection-and vaccine-induced immunity target different parts of the 69 SARS-CoV-2 spike protein, including the receptor binding domain (RBD), the N-terminal domain (NTD), 70 and the S2 domain (10-15). Most described neutralizing epitopes can be found on the RBD and the NTD, 71

while very few S2 directed antibodies neutralize the virus in vitro (12, 16, 17) . Furthermore, it has been 72

shown that the ratio of neutralizing to non-neutralizing antibodies differs between natural infection and 73 mRNA vaccination (10, 15). While mRNA vaccination induces higher absolute neutralizing antibody titers 74 in serum, infection induces a higher proportion of neutralizing antibodies. In other words, a large 75 percentage of mRNA vaccine-induced antibodies bind spike but do not neutralize the virus, while this 76 percentage is lower after natural infection. In addition, it is known that, while neutralizing activity can be 77 drastically reduced against viral variants, binding activity is better retained (18, 19) . In this case, of course, 78 the ratio between neutralizing and non-neutralizing antibodies also changes. While both neutralizing and 79

binding antibodies have been implicated as correlates of protection (20), only neutralizing antibodies are 80

likely to block infection. 81

Here we performed a secondary analysis comparing sera from individuals vaccinated with NDV-HXP-S in 82 Thailand to sera from convalescent and mRNA vaccinated individuals collected under observational cohort 83 studies in New York City (e.g., PARIS study (21)) to investigate neutralizing activity, ratios of binding to 84 neutralizing antibodies and activity against variants of concern. 85 Results 86

Two sets of sera where used for this study. The first set comprised of sera from a clinical trial in Thailand 88 (NCT04764422) (9) which included six groups: a placebo control group (n=35), a group that received 1μg 89 of inactivated NDV-HXP-S (n=35), a group that received 1μg plus ODN1018 adjuvant (n=35), a group that 90 received 3μg (n=35), a group that received 3 μg plus ODN1018 (n=35) and a group that received 10μg of 91 NDV-HXP-S (n=35). Individuals were vaccinated twice, on day 1 and day 29; sera tested were collected 92 two weeks after the boost (day 43 and New York were comparable (Table 1) . 99

Neutralizing activity against wild type SARS-CoV-2 of sera from NDV-HXP-S vaccinees is similar to that 100 of sera from BNT162b2 vaccinees 101 First, we tested the neutralizing activity of the sera from the NDV-HXP-S trial (placebo, 1μg, 1 μg + 102 ODN1018, 3μg, 3μg + ODN1018, and 10μg) as well as the BNT162b2 and the human convalescent sera 103 (HCS) against wild type SARS-CoV-2. Few individuals in the placebo control group had detectable 104 neutralizing activity (8/35), and those who were positive had a low titer resulting in a 50% inhibitory 105 dilution (ID 50 ) geometric mean titer (GMT) of 1:5.9 ( Figure 1A) . NDV-HXP-S ID 50 titers ranged from 1:73.4 106 (1μg) to 1:231.1 (10μg). A difference between adjuvanted and nonadjuvanted formulations was only 107

found for the 3μg dose with 1:123.0 and 1:101.1 GMT, respectively. BNT162b2 recipient sera had a GMT 108 of 1:146.8, whereas the HCS had a GMT of 1:68.0. While these differences were large, no statistical 109 significance between the groups could be established in a one-way ANOVA when corrected for multiple 110

comparisons due to small group size. Similar activity was detected against the B.1.617.2 (Delta) and 111 B.1.351 (Beta) variants, although -as expected -with reduced titers (Figure 1B and C) . 112

Binding activity of sera from NDV-HXP-S vaccinees is lower than that of sera from BNT162b2 vaccinees 113 Next, we assessed binding to wild type spike protein using the commercial SeroKlir Kantaro Semi-114

Quantitative SARS-CoV-2 IgG Antibody Kit (22). Interestingly, binding antibody titers were much lower in 115 this binding assay for the NDV-HXP-S vaccinees as compared to the BNT162b2 vaccinees (Figure 2A) . 116 Furthermore, the 10μg group was on par with the HCS group while other vaccine groups were slightly 117 lower than the convalescents. To confirm these findings, we also tested binding to wild type spike in a 118 research grade enzyme linked immunosorbent assay (ELISA) (23) (Figure 2B) . Similar to what we observed 119 in the Kantaro assay, the NDV-HXP-S vaccine induced decreased binding titers against wild type full-length 120 spike compared to the BNT162b2 vaccine ( Figure 2B) . We also tested binding to an extensive array of 121 variant spike proteins ( Figure 2B ). While binding was maintained across all variants tested, this pattern of 122 lower binding activity of sera from NDV-HXP-S vaccinees was seen across the board. 123 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint

The NDV-HXP-S vaccine induces an antibody response that consists of a high proportion of 124 neutralizing antibodies 125

Since the neutralizing antibody titers of sera from NDV-HXP-S and BNT162b2 vaccinees were similar, and 126 binding titers were much lower for NDV-HXP-S, we decided to determine ratios between binding and 127 neutralizing titers (binding titers taken from Figure 2B , neutralizing titers taken from Figure 1A ). As 128 observed before (10, 15), the ratio of binding to neutralizing antibodies was much better (lower, indicating 129 a higher proportion of neutralizing antibodies) in convalescent individuals as compared to individuals 130 vaccinated with BNT162b2 (Figure 3) . Surprisingly, the ratio of binding to neutralizing antibodies in NDV-131 HXP-S vaccinated individuals was similar to or even better than that of convalescent individuals, 132

suggesting that a large proportion of the antibodies induced by this vaccine had neutralizing activity. To 133 confirm these findings, randomly selected samples from the complete sample set were sent to an 134 independent laboratory (the Suthar laboratory at Emory University) for validation of our findings. The 135

laboratory was asked to measure binding and neutralization activities but the provided samples were 136 blinded, and the reason for running the samples was not disclosed. The neutralization assay used in this 137 second laboratory consisted of a focus reduction neutralization assay (FRNT), and the binding assay used 138 was based on the MesoScale Discovery platform, in contrast to the microneutralization assay and ELISA 139 used at Mount Sinai. While the ratios themselves were different (as to be expected due to the different 140 methods used), the difference between convalescent sera and sera from mRNA vaccinated individuals 141 was maintained ( Figure 3B ). Sera from NDV-HXP-S vaccinated individuals again showed ratios similar to 142 sera from convalescent individuals. We also assessed these ratios for the Delta and Beta variants since 143 both specific neutralizing activity and binding to the respective variant spikes were available. The pattern 144 seen with wild type SARS-CoV-2 was also observed with these two viral variants (Figure 3C and D) . 145 Importantly, the ratios of binding to neutralizing activities in sera from BNT162b2 vaccinated individuals 146

were significantly different from ratios measured in sera from NDV-HXP-S vaccinated or from 147 convalescent individuals. 148

To determine which domains of the spike protein are targeted in convalescent, BNT162b2 mRNA 150 vaccinated, and NDV-HXP-S vaccinated individuals we then performed ELISAs against recombinant RBD, 151 NTD, and S2 proteins. Sera from all NDV-HXP-S vaccine regimens as well as BNT162b2 vaccination and 152 natural infection, displayed strong RBD titers, albeit at different magnitudes ( Figure 4A ). NTD antibodies 153

were predominantly only present at high titers in BNT162b2 vaccinated individuals ( Figure 4B ). Finally, S2 154 antibodies were strongly induced by natural infection and by BNT162b2 vaccination but to a much lower 155 degree by NDV-HXP-S vaccination ( Figure 4C) . These data suggest that the strong neutralizing activity after 156 NDV-HXP-S vaccination is likely driven by an RBD-focused response. 157

During the COVID-19 pandemic, global vaccine distribution and vaccine equity were, and continue to be, 159

suboptimal. Locally produced vaccines can increase vaccine access and vaccine independence, especially 160

for LMICs. The NDV-HXP-S vaccine is designed to help close this gap since it can be economically produced 161

in influenza vaccine manufacturing plants that are located in LMICs. Moreover, it can be stored and 162 distributed without the need for freezers and incorporates an advanced HexaPro antigen design 163 compared to most other COVID-19 vaccines on the market (3). The NDV-HXP-S vaccine development 164

program also provides a vaccine platform and model that can be used for optimal pandemic preparedness 165 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint and response in LMICs in the future. Importantly, here we show that an inactivated version of the NDV-166 HXP-S vaccine is capable of inducing neutralizing antibody titers in humans that are comparable to titers 167 induced by the BNT162b2 mRNA vaccine (Pfizer). Interestingly, while the induced neutralizing activity is 168 comparable with mRNA vaccination, the binding antibody titers are much lower. This results in a response 169 dominated by neutralizing antibodies, as observed when comparing ratios of binding to neutralizing 170 antibody titers. It has been shown previously by our team and others, that mRNA vaccination -while 171

inducing very high and protective neutralizing antibody titers -also induces a large quantity of non-172 neutralizing antibodies that, on a monoclonal level, target RBD, NTD, and S2 (10, 15). In fact, while 173 neutralizing titers after natural infection are usually lower than after mRNA vaccination, the ratio of 174 binding to neutralizing antibodies is more favorable. Here, we observe comparable ratios for convalescent 175 individuals and NDV-HXP-S vaccinated individuals, while the ratios for mRNA vaccinees are significantly 176 different. We confirmed these findings by using two different assay formats conducted in independent 177

research laboratories for measuring both binding and neutralization activity. When analyzing the 178 polyclonal response for binding to RBD, NTD, and S2, we found that mRNA vaccination induces strong 179

immune responses against all three targets; natural infection mostly targets RBD and S2, while NDV-HXP-180 S targets almost exclusively the RBD. This explains the high proportion of neutralizing antibodies since 181 most epitopes targeted by neutralizing antibodies are located in the RBD. There could be two reasons for 182 this very focused immune response. First, presentation of the spike on the NDV particle could limit access 183 of B-cell receptors to the extreme membrane distal part of the spike protein -which is the RBD. Akin to a 184 dense forest of mature trees, the NDV-HXP-S particles are likely densely packed with NDV hemagglutinin-185 neuraminidase (HN), NDV fusion protein (F), and SARS-CoV-2 spike protein. It is easy to imagine, that B-186 cell receptors, which are also surrounded by many other membrane proteins on the surface of B-cells, 187 could be sterically hindered from reaching the membrane proximal S2 domain or the NTD, which is also 188 located closer to the membrane than the RBD. The second hypothesis is, that the HexaPro antigen design 189

(3), which arrests the spike protein in the pre-fusion conformation, leads to a refocusing of the antibody 190 response to the RBD. Many S2 epitopes may only be accessible in the post-fusion conformation and may 191 be exposed in wild type spike or the metastable (2P) spike included in mRNA vaccines. These S2 epitopes 192 may distract the immune responses from the RBD. A pre-fusion stabilized spike like the HexaPro may not 193 display these epitopes, hence focusing most of the immune response to the RBD. Of course, the effect 194 observed could also be caused by a combination of both mechanisms. 195

Our study has several limitations. We include a limited number of samples, and our dataset comes from 196 a comparison of imperfectly matched groups from a clinical trial in Thailand and an observational cohort 197 study in New York City. Strengths of the study include the use of authentic SARS-CoV-2 for neutralization 198 assays and that the findings could be replicated with different methods in a different, blinded, and 199 independent laboratory. 200

In summary, we show that a vaccine candidate which can be produced locally in LMICs at low cost induces 201

neutralizing antibody titers to SARS-CoV-2 comparable to those observed in cohorts having received 202 mRNA-based COVID-19 vaccines. The NDV-HXP-S vaccine candidate induces a strong RBD focused immune 203 response resulting in a high proportion of neutralizing antibodies, which are associated with protection 204 from infection and severe disease (20, 24, 25). 205 206 207 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint

Human Serum Samples. Sera collected from the NDV-HXP-S clinical trial in Thailand (placebo, 1μg, 1 μg + 209 ODN1018, 3μg, 3μg + ODN1018, and 10μg, n=35 samples per group) were used in this study. 210

Characteristics of the clinical trial samples are indicated in Table 1 . Additional detail can be found in the 211 published interim report (9). In addition, we selected convalescent (n=18) and post-vaccine sera (n=20) 212 that were collected from participants in two longitudinal observational studies. The BNT162b2 vaccinees 213

were selected from the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort (21) concern, the designated amino acid substitutions corresponding to each variant were introduced into the 248

Wuhan-1 sequence and purified as described above. 249 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. spike calibrators used to generate a standard curve, were added to every microtiter plate. After 2 hours 289 of incubation at room temperature, the remaining steps of the ELISA were performed as described above. 290

Data were analyzed using GraphPad Prism 9. The concentration of spike-reactive antibodies was 291 calculated using a four parameter logistic (4-PL) curve-fit. Samples exceeding the range of the standard 292 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. in PBS, 1% BSA wasadded at a 1:2,000 dilution. Following a 1 hour incubation at RT, cells were washed 318 twice with PBS, and 100μl/well of Sigmafast OPD were added for 10min at RT. Addition of 50μl/well of a 319 3M HCl solution (Thermo Fisher Scientific) allowed to stop the reaction. The optical density (OD) was 320 measured (490 nm) using a microplate reader (Synergy H1; Biotek). All the analyses were performed using 321

Prism 7 software (GraphPad). A nonlinear regression curve fit analysis was performed to calculate the 322 inhibitory dilution 50% (ID 50 ). 323 anti-SARS-CoV spike primary antibody directly conjugated to Alexafluor-647 (CR3022-AF647) for up to 4 335 hours at room temperature. Cells were washed three times in PBS and foci were visualized on a CTL 336 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint Analyzer. Antibody neutralization was quantified by counting the number of foci for each sample using 337 the Viridot program (31). The neutralization titers were calculated as follows: 1 -(ratio of the mean 338 number of foci in the presence of sera and foci at the highest dilution of respective sera sample). Each 339 specimen was tested in duplicate. The FRNT 50 titers were interpolated using a 4-parameter nonlinear 340 regression in GraphPad Prism 9.2.0. Samples that do not neutralize at the limit of detection at 50% were 341 plotted at 10 for geometric mean and fold-change calculations. 342

Multiplex Immunoassay. Serum samples were tested for their IgG binding against the SARS-CoV-2 343

Wuhan-1 strain using an electro chemiluminescent-based multiplex immunoassay provided by Mesoscale 344

Discovery (MSD-ELICA Statistical analyses were performed using Prism 9 software (GraphPad). 359

All data produced in the present study are available upon reasonable request to the authors. 361

We thank the study participants of the vaccine trial, the PARIS cohort and our longitudinal observational 363 cohort for their generosity and willingness to help advance our knowledge on SARS-CoV-2 immune 364 responses. We thank Dr. Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility 365

at Mount Sinai, which makes our work with live SARS-CoV-2 possible. We are also grateful for Mount 366

Sinai's leadership during the COVID-19 pandemic. We want to especially thank Drs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 28, 2022. In A, binding to wild type spike protein was assessed using the SeroKlir Kantaro Semi-Quantitative SARS-488

CoV-2 IgG Antibody Kit . In B, a research grade ELISA was used to assess binding to wild type as well as 489 variant spike proteins. For vaccine groups N=35, 20 individuals were included in the BNT162b2 group and 490 sera from 18 individuals were included in the HCS group. The exception was the BNT162b2 group for 491 which N was 18 in A. Bars show geometric mean titers (GMT), error bars indicate standard deviation of 492 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint the GMT. The dotted line indicates the limit of detection; values below the limit of detection were 493 assigned a value of half of the limit of detection. 494 Figure 3 : Ratios of binding to neutralizing activity. A shows ratios between binding and neutralizing 495 activity for wild type SARS-CoV-2. Binding was analyzed using a research grade ELISA ( Figure 2B ) and 496 neutralization was assessed using a microneutralization assay ( Figure 1A) . B shows a subset of samples 497 analyzed blindly in an independent laboratory using the MesoScale Discovery platform for binding and an 498 FRNT 50 assay for neutralization. C shows ratios for Delta using Delta binding and neutralization data (from 499 Figures 2B and 1B) and D shows ratios for Beta using Beta binding and neutralization data (from Figures  500  2B and 1C ). Geometric mean ratios are shown; error bars indicate standard deviation of the GMR. For 501 vaccine groups N=35, 20 individuals were included in the BNT162b2 group and sera from 18 individuals 502

were included in the HCS group. The exception was B for which a subset of 19 NDV-HXP-S samples was 503 tested and the N for BNT162b2 and HCS was 12. In addition, in C the N for the 3 ug group is 34 and in D 504

the N for the 1ug and 1ug+ODN1018 is 34 and for the 3 ug group it is 31 due to the lack of neutralization 505 data. Statistical analysis was performed using a one-way ANOVA corrected for multiple comparisons. 506 Statistical significant differences are indicated in the figure. 507 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 28, 2022. ; https://doi.org/10.1101/2022.01.25.22269808 doi: medRxiv preprint

SARS-CoV-2 vaccines in development

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 403 induces protective immune responses

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Global production capacity of seasonal and pandemic influenza vaccines in 407 2019

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a 409 Cost-Effective Inactivated SARS-CoV-2 Vaccine

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live 411 virus vaccine candidate

Safety and Immunogenicity Analysis of a Newcastle Disease Virus

Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based 416 SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. mBio

Safety and Immunogenicity of an Inactivated Recombinant Newcastle 419

Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-420 Controlled, Phase 1/2 Trial. medRxiv

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, 422 RBD, and S2

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal 424 domain target a single supersite

Isolation and characterization of cross-neutralizing coronavirus 426 antibodies from COVID-19+ subjects

N-terminal domain antigenic mapping reveals a site of vulnerability for 428 SARS-CoV-2

Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA 431 vaccination

Broad betacoronavirus neutralization by a stem helix-specific human antibody

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, 435 RBD, and S2

Evidence for retained spike-binding and neutralizing activity against 437 emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Evidence for antibody as a protective correlate for COVID-19 vaccines

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 444 mRNA Vaccine

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 446 seroprevalence using multiple serology platforms

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological 448

Antigen Production, and Test Setup

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy 450 clinical trial

Neutralizing antibody levels are highly predictive of immune protection from 452 symptomatic SARS-CoV-2 infection

A serological assay to detect SARS-CoV-2 seroconversion in humans

Rapid decline of neutralizing antibodies is associated with decay of IgM 456 in adults recovered from mild COVID-19

Development of a Rapid Focus Reduction Neutralization Test Assay for 458

Measuring SARS-CoV-2 Neutralizing Antibodies

Infection-and vaccine-induced antibody binding and neutralization of the 460 B.1.351 SARS-CoV-2 variant

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-462

CoV-2 B.1.617 Variants

Viridot: An automated virus plaque (immunofocus) counter for the 464 measurement of serological neutralizing responses with application to dengue virus